Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | CTSG | P08311 | 2/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587804 | 0.90 | GPR84 (0.44) | CSNK1ECES2CES1ALDH1A1NAAA | |
| SCHEMBL28204364 | 0.90 | GPR84 (0.44) | CSNK1ECES2CES1ALDH1A1NAAA | |
| SCHEMBL5711604 | 0.85 | CSNK1E (0.39) | CSNK1ECES2CES1ALDH1A1NAAA | |
| SCHEMBL7597024 | 0.81 | CES2 (0.41) | ACE2CSNK1ECES2CES1ALDH1A1 | |
| SCHEMBL8903692 | 0.81 | CES2 (0.41) | ACE2CSNK1ECES2CES1ALDH1A1 | |
| SCHEMBL3844012 | 0.80 | ACE2 (0.53) | ACE2CSNK1ECES2CES1ALDH1A1 | |
| SCHEMBL12482425 | 0.80 | CSNK1E (0.41) | CSNK1ECES2CES1ALDH1A1NAAA | |
| SCHEMBL12485912 | 0.80 | CSNK1E (0.41) | CSNK1ECES2CES1ALDH1A1NAAA | |
| SCHEMBL8910003 | 0.79 | CES2 (0.40) | CSNK1ECES2CES1ALDH1A1NAAA | |
| SCHEMBL5706450 | 0.79 | POLB (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1251818-B9 | GALENIC FORMULATION | MERCK PATENT GMBH (DE) | 2009-01-07 | — | — | EP | claimed |
| US-20080199414-A1 | COSMETIC FORMULATION COMPRISING FLAVONOID DERIVATIVES | WIRTH CORINNA | 2008-08-21 | — | — | US | claimed |
| EP-1267819-B1 | Quinoxaline derivatives, compositions containing them und use as UV-filter | MERCK PATENT GMBH (DE) | 2008-08-06 | — | — | EP | claimed |
| EP-1251818-B1 | GALENIC FORMULATION | MERCK PATENT GMBH (DE) | 2008-07-02 | — | — | EP | claimed |
| EP-1373270-B1 | TRICYCLIC QUINOXALINE DERIVATIVES AS A UV FILTER | MERCK PATENT GMBH (DE) | 2007-06-06 | — | — | EP | claimed |
| EP-1566175-B1 | Topical preparation comprising at least one aryloxime and bisabolol | MERCK PATENT GMBH (DE) | 2006-10-25 | — | — | EP | claimed |
| US-20050249761-A1 | Topical composition comprising at least one aryl oxime and bisabolol | MERCK PATENT GESELLSCHAFT MIT BECHRANKTER HAFTUNG (DE) | 2005-11-10 | — | — | US | claimed |
| EP-1566175-A1 | Topical preparation comprising at least one aryloxime and bisabolol | MERCK PATENT GmbH (DE) | 2005-08-24 | — | — | EP | claimed |
| US-6903134-B2 | Formulation comprising benzofuranone derivatives for protection against oxidative stress | MERCK PATENT GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| EP-1250331-B1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-11-03 | — | — | EP | claimed |
| US-20030060426-A1 | Formulation for protection against oxidative stress containing benzofuranone derivatives | MERCK PATENT GMBH (DE) | 2003-03-27 | — | — | US | claimed |
| US-20030039619-A1 | Galenic formulation | MERCK PATENT GMBH (DE) | 2003-02-27 | — | — | US | claimed |
| EP-1267819-A2 | PREPARATION CONTAINING QUINOXALINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-01-02 | — | — | EP | claimed |
| EP-1251818-A1 | GALENIC FORMULATION | MERCK PATENT GmbH (DE) | 2002-10-30 | — | — | EP | claimed |
| WO-2002069926-A1 | COSMETIC FORMULATIONS CONTAINING FLAVONOID DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-09-12 | — | — | WO | claimed |
| WO-2001068047-A2 | PREPARATION CONTAINING QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2001-09-20 | — | — | WO | claimed |
| WO-2001054653-A1 | GALENIC FORMULATION | MERCK PATENT GMBH (DE) | 2001-08-02 | — | — | WO | claimed |
| EP-0389773-B1 | PROCESS FOR PREPARING A GALENIC FORMULATION OF 2-HYDROXY-5-METHYLLAUROPHENONOXIME WITH OPTIMAL BIOAVAILABILITY | Salutas Fahlberg-List Pharma GmbH (DE) | 1993-09-22 | — | — | EP | claimed |
| EP-0389773-A2 | Process for preparing a galenic formulation of 2-hydroxy-5-methyllaurophenonoxime with optimal bioavailability | Salutas Fahlberg-List Pharma GmbH (DE) | 1990-10-03 | — | — | EP | claimed |
| US-4816487-A | ANTIALLERGENS | HUMBOLDT-UNIVERSITAET ZU BERLIN (DD) | 1989-03-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060426-A1 | Formulation for protection against oxidative stress containing benzofuranone derivatives | NQO1, NFE2L2, GPX4 | ACE2 3385/4885CSNK1E 2493/4885CES2 2482/4885 |
| US-20030039619-A1 | Galenic formulation | GALR2, GALE, GLA | ACE2 2563/4885CSNK1E 1293/4885CES2 306/4885 |
| US-20050249761-A1 | Topical composition comprising at least one aryl oxime and bisabolol | TYR, CYP1B1, AHR | ACE2 1323/4885CSNK1E 1692/4885CES2 147/4885 |
| US-20080199414-A1 | COSMETIC FORMULATION COMPRISING FLAVONOID DERIVATIVES | TYR, MITF, TEAD3 | ACE2 1632/4885CSNK1E 4211/4885CES2 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.